ValuEngine upgraded shares of Amyris (NASDAQ:AMRS) from a hold rating to a buy rating in a research note issued to investors on Thursday morning.
A number of other research analysts have also recently issued reports on the stock. HC Wainwright reissued a buy rating and set a $15.00 price target on shares of Amyris in a research report on Tuesday, June 26th. BidaskClub raised shares of Amyris from a sell rating to a hold rating in a research report on Wednesday, June 20th. Zacks Investment Research cut shares of Amyris from a hold rating to a strong sell rating in a research report on Monday, June 4th. Finally, B. Riley set a $10.00 price target on shares of Amyris and gave the company a buy rating in a research report on Tuesday, May 29th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company’s stock. Amyris presently has a consensus rating of Buy and a consensus price target of $9.13.
Shares of NASDAQ AMRS opened at $6.39 on Thursday. Amyris has a 1 year low of $1.86 and a 1 year high of $7.30. The company has a debt-to-equity ratio of -0.35, a current ratio of 0.67 and a quick ratio of 0.62.
Amyris (NASDAQ:AMRS) last issued its quarterly earnings results on Monday, May 14th. The biotechnology company reported ($1.79) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($1.31). The company had revenue of $23.00 million for the quarter, compared to the consensus estimate of $24.12 million. During the same period in the prior year, the business posted ($0.13) earnings per share. Amyris’s revenue for the quarter was up 77.2% compared to the same quarter last year. equities analysts forecast that Amyris will post -1.92 EPS for the current fiscal year.
In related news, major shareholder (Mauritius) Pte Ltd Maxwell sold 95,162 shares of Amyris stock in a transaction dated Monday, May 7th. The shares were sold at an average price of $6.54, for a total transaction of $622,359.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 21.80% of the company’s stock.
A number of institutional investors have recently modified their holdings of AMRS. Hudson Bay Capital Management LP purchased a new position in Amyris in the fourth quarter worth about $451,000. Compagnie Lombard Odier SCmA raised its holdings in Amyris by 60.0% in the fourth quarter. Compagnie Lombard Odier SCmA now owns 104,000 shares of the biotechnology company’s stock worth $390,000 after buying an additional 39,000 shares during the last quarter. B. Riley Financial Inc. purchased a new position in Amyris in the first quarter worth about $294,000. Crown Advisors Management Inc. purchased a new position in Amyris in the first quarter worth about $669,000. Finally, KBC Group NV raised its holdings in Amyris by 37.4% in the first quarter. KBC Group NV now owns 62,465 shares of the biotechnology company’s stock worth $418,000 after buying an additional 16,995 shares during the last quarter. 23.72% of the stock is owned by institutional investors and hedge funds.
Amyris Company Profile
Amyris, Inc provides various alternatives to a range of petroleum-sourced products worldwide. The company uses its industrial bioscience technology to design microbes primarily yeast, as well as to convert plant-sourced sugars into renewable ingredients. It produces and sells Biofene that converts to squalane, which is used as an emollient in cosmetics and other personal care products; and natural oils and aroma chemicals for the flavors and fragrances market.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.